Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis

Abstract

Cytoreductive prostatectomy had gained a lot of interest in treatment of metastatic prostate cancer (mPCa) but this treatment approach is still in the experimental phase. This systematic review and meta-analysis was conducted to shed light on the merits of cytoreductive radical prostatectomy compared to systemic and radiation therapy in treatment of mPCa. In February 2021, summary data from 12 original research papers covering 100,973 patients is abstracted. PubMed/Medline, Scopus, Google Scholar, EMBASE, and the Cochrane Library were all reviewed and 12 publications were chosen for inclusion. The evaluated outcomes were 1-, 3-, and 5-year Cancer-Specific (CSS) and overall survival (OS) rates. Cytoreductive radical prostatectomy had significantly higher survival rate for 1-year (OR: 3.03; 95% CI: 2.30–3.98; p < 0.001), 3-year (OR: 2.47; 95% CI: 2.14–3.51; p < 0.001), and 5-year CSS rates (OR: 2.90; 95% CI: 2.10–4.01; p < 0.001) than systemic therapy in mPCa. Higher significant rates of 1-year (OR: 2.35; 95% CI: 1.65–3.36; p < 0.001), three-year (OR: 2.25; 95% CI: 1.96–2.60; p < 0.001), and 5-year OS rates (OR: 2.54; 95% CI: 2.10–3.08; p < 0.001) were also detected for cytoreductive radical prostatectomy compared to systemic therapy. There were no significant differences in 1-year (OR: 1.21; 95% CI: 0.88–1.66; p = 0.25), 3-year (OR: 1.21; 95% CI: 0.92–1.59; p = 0.18), and 5-year CSS rates (OR: 0.91; 95% CI: 0.58–1.42; p = 0.67) between cytoreductive radical prostatectomy and radiation in mPCa patients. Also, no significant differences in 1-year (OR: 1.06; 95% CI: 0.77–1.47; p = 0.71), 3-year (OR: 0.83; 95% CI: 0.60–1.14; p = 0.25), and 5-year OS rates (OR: 1.84; 95% CI: 0.76–4.45; p = 0.18) were detected between cytoreductive radical prostatectomy and radiation therapy. Cytoreductive radical prostatectomy had significantly higher 1-, 3-, and 5-year CSS and OS rates compared to systemic therapy. Comparable CSS and OS rates were found between cytoreductive radical prostatectomy and radiation therapy.

Keywords

Cytoreductive radical prostatectomy metastatic prostate cancer radiation ablation

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Fedewa

, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017; 67(3): 177–193.

Sharifi

Gulley

Dahut

WL.

Androgen deprivation therapy for prostate cancer. JAMA 2005; 294(2): 238–244.

Fish

Evans

, et al. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014; 120(6): 818–823.

Glehen

Mohamed

Gilly

FN.

Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004; 5(4): 219–228.

Bristow

Tomacruz

Armstrong

, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5): 1248–1259.

Flanigan

Salmon

Blumenstein

, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New Engl J Med 2001; 345(23): 1655–1659.

Culp

Schellhammer

Williams

MB.

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014; 65(6): 1058–1066.

Gratzke

Engel

Stief

CG.

Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 2014; 66(3): 602–603.

Qin

, et al. Tumor cytoreduction results in better response to androgen ablation—a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol 2012; 30(2): 145–149.

10.

Moschini

Morlacco

Kwon

, et al. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis 2017; 20(1): 117–121.

11.

Heidenreich

Pfister

Porres

Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. Urol J 2015; 193(3): 832–838.

12.

Poelaert

Verbaeys

Rappe

, et al. Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective local treatment of metastatic prostate cancer (LoMP) trial. Urology 2017; 106: 146–152.

13.

Steuber

Berg

Røder

, et al. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus 2017; 3(6): 646–649.

14.

Satkunasivam

Kim

Desai

, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. Urol J 2015; 194(2): 378–385.

15.

Parikh

Byun

Goyal

, et al. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate 2017; 77(6): 559–572.

16.

Rusthoven

Jones

Flaig

, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 2016; 34(24): 2835–2842.

17.

Antwi

Everson

TM.

Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 2014; 38(4): 435–441.

18.

Leyh-Bannurah

Gazdovich

Budäus

, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol 2017; 72(1): 118–124.

19.

Shao

Kim

Moore

, et al. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol 2014; 65(4): 693–700.

20.

Jung

Kim

Shiozawa

, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013; 4: 1795.

21.

Kim

Oskarsson

Acharyya

, et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139(7): 1315–1326.

22.

Danna

Sinha

Gilbert

, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004; 64(6): 2205–2211.

23.

Tzelepi

Efstathiou

Wen

, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 2011; 29(18): 2574–2581.

24.

Gleave

Goldenberg

Chin

, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. Urol J 2001; 166(2): 500–506; discussion 506–507.

25.

Fossati

Trinh

Sammon

, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol 2015; 67(1): 3–6.

26.

Sylvester

Canfield

Lam

, et al. Conflict of evidence: resolving discrepancies when findings from randomized controlled trials and meta-analyses disagree. Eur Urol 2017; 71: 811–819.